In 2020, Goldman Sachs made a big splash by declaring the bank would refuse to take a company public if the business didn't ...

Blink Charging (BLNK) has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission to sell shares ...

Median returns three months post IPO 2024 performance (the green line in Chart 5) were much better than the last two years (purple and pink lines). Importantly, 2024 IPOs as a group have so far held ...

Cybersecurity firm SailPoint said on Tuesday it is now seeking a valuation of up to $12.57 billion in its U.S. initial public ...

Nasdaq reported higher fourth-quarter profit on Wednesday, helped by increased demand for the exchange operator's financial ...

Hotel101 Global—a unit of DoubleDragon, which is jointly owned by Philippine fast food giant Jollibee founder Tony Tan ...

Key Takeaways Cybersecurity firm SailPoint is reportedly targeting an IPO valuation of up to $11.5 billion.SailPoint and ...

Cystic-fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity ...

The first Israeli IPO on . Nasdaq. in 2025 is expected to take place soon, when tech company Odysight.ai (OTC: ODYS) will ...

Weight loss drug developer Metsera is targeting $289m in its Nasdaq IPO while Maze Therapeutics has outlined plans for a $131m listing, and Ascentage Pharma – already listed in Hong Kong – started ...

Maze Therapeutics became the latest drug developer to list in New York on Friday, with its shares rising nearly 1% in their debut, giving the company a valuation of $690.37 million. The muted market ...